Compare Citius Pharmaceuticals Inc (CTXR) vs Vistra Corp (VST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Vistra Corp — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while Vistra Corp trades at $158.51 (market cap $52.41B). The key difference: Vistra Corp is far larger — about 3848× Citius Pharmaceuticals Inc's market cap, and Vistra Corp pays a 0.59% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Vistra Corp for 32 Days on average.
| CTXR | VST | |
|---|---|---|
Market Cap | $13.62M | $52.41B |
Volume | 132,438 | 11,278,074 |
Sector | Health | Utilities |
52-Week High | $1.82 | $210.85 |
52-Week Low | $0.48 | $134.71 |
Typical Hold Time | 16 Days | 32 Days |
Enterprise Value | $3.79M | $74.34B |
Dividend Yield | — | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
Vistra Corp (VST) trades at $166.72, up 3.88% with strong analyst support (91% buy ratings) and a $215.23 consensus target. The stock shows bullish technical momentum above key support at $162, while fundamentals reveal impressive 75.73% ROE and 11.55% net margin. Recent developments include a $4.2 billion US loan for nuclear expansion and a 20-year power deal with New Era Energy, positioning VST to capitalize on AI-driven electricity demand.
Vistra offers compelling exposure to the AI power infrastructure theme with strong profitability and government backing, though investors face earnings volatility risks as seen in recent quarterly misses. The stock trades at a premium valuation (P/E 26.33) but maintains upside potential if execution on nuclear expansion and data center contracts meets expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Vistra Corp
Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.
Read more on VST →
